MedTrace Logo

A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study

NCT03382431 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2018-05-16

No results posted yet for this study

Summary

PC786 is a new medicine being developed for treatment of respiratory syncytial virus. The main purpose of this study is to evaluate the antiviral activity of PC786 in healthy adults infected with RSV virus in a viral challenge study.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

DRUG

PC786

Repeat doses

DRUG

Placebo/vehicle

Repeat doses

Sponsors & Collaborators

  • Pulmocide Ltd

    lead INDUSTRY

Principal Investigators

  • Bryan J Murray, MBBS · hVIVO Services Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-14
Primary Completion
2018-05-09
Completion
2018-05-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03382431 on ClinicalTrials.gov